Eleanor Health is a technology company.
Eleanor Health has raised $112.0M across 4 funding rounds.
Eleanor Health has raised $112.0M in total across 4 funding rounds.
Eleanor Health is a technology-enabled healthcare company providing outpatient addiction and mental health treatment, focusing on substance use disorders (SUD) through a whole-person, evidence-based model.[1][2][3] It serves adults facing addiction by delivering medications for addiction treatment (MAT) like Suboxone and Vivitrol, psychiatry, therapy, peer recovery coaching, care coordination, and wellness support—both virtually and in-person—to address physical, mental, and psychosocial needs while reducing total cost of care.[2][4][5] The company solves barriers in traditional recovery programs, such as fee-for-service models, short-term abstinence focus, and high costs, by using value-based payments, harm reduction, and longitudinal care for sustained recovery.[2][5] With operations in over a dozen states, contracts with 17 payers including Cigna, and $30 million raised in 2024, Eleanor demonstrates strong growth momentum through expanded payer partnerships and clinical outcomes like reduced cravings and improved urine screenings.[2][5][8]
Eleanor Health launched in 2019 in North Carolina, founded by CEO and Co-Founder Corbin Petro—a healthcare innovator and former Founding CEO of Benevera Health—and Co-Founder and CMO Dr. Nzinga Harrison.[1] Petro envisioned treating addiction as a chronic illness requiring long-term management, leveraging data and technology to enhance in-person care, while Harrison emphasized community ties and whole-person outcomes beyond remission.[1] The idea emerged from recognizing gaps in evidence-based SUD treatment, with the name "Eleanor" symbolizing "shining light" in Greek and honoring Eleanor Roosevelt's advocacy for medical care rights.[1] Early traction included welcoming the first patients in Mooresville, NC, integrating with local communities, and rapid national expansion starting in 2020 across states like LA, MA, NJ, NC, OH, TX, and WA.[1][2]
Eleanor Health rides the wave of value-based behavioral health tech, addressing the U.S. addiction crisis amid rising SUD prevalence post-opioids and COVID, where traditional models fail on cost and efficacy.[2][5] Timing aligns with payer shifts to outcomes-based reimbursement and telehealth normalization, enabling scalable, tech-enhanced care that influences ecosystems by partnering with giants like Cigna (covering 4.7M lives, 366K with SUD needs) and General Catalyst.[2][5] Market forces favoring it include regulatory pushes for MAT access, demand for longitudinal SUD management, and tech's role in coordination—positioning Eleanor to lower national healthcare costs while setting standards for integrated behavioral health platforms.[1][2]
Eleanor Health is poised for accelerated national scaling, building on $30M funding and payer expansions to enter more states, refine AI-driven personalization, and deepen outcomes data for broader adoption.[2][5] Trends like AI in care coordination, further payer consolidation, and mental health parity laws will amplify its model, potentially evolving it into a dominant SUD platform influencing policy and competitors toward value-based, tech-integrated care. This transforms addiction treatment from episodic to lifelong support, echoing its launch promise of helping people "live amazing lives."[1][3]
Eleanor Health has raised $112.0M in total across 4 funding rounds.
Eleanor Health's investors include F-Prime Capital Partners, General Catalyst, Khosla Ventures, Matthew McAviney, OrbiMed, Animo Ventures, Avalanche VC, Broadstone, Darling Ventures, eFounders, Jenny Fielding, Scott Hartley.
Eleanor Health has raised $112.0M across 4 funding rounds. Most recently, it raised $30.0M Series D in February 2024.